文献速递创伤与烧伤复苏、休克与脓毒症

创伤大输血患者使用A型应急释放血浆

Group A emergency-release plasma in trauma patients requiring massive transfusion.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论在需要大输血的创伤患者中,A型应急释放血浆与AB型相比未增加血栓栓塞率(HR 0.52),死亡率与非致命并发症结果不确定,A型是可接受选择。

该研究为Pragmatic, Randomized, Optimal Platelet and Plasma Ratios试验的二次分析,纳入680例预测需大输血的创伤患者,其中584例(85.9%)接受至少1 U应急释放血浆,462例(79.1%)接受AB型、122例(20.9%)接受A型。以HR 1.35为非劣效界值,A型相比AB型未增加血栓栓塞率(HR 0.52;95%CI 0.31-0.90),死亡率(HR 1.15;95%CI 0.91-1.45)与非致命并发症(HR 1.24;95%CI 0.87-1.77)结果不确定。亚组分析中,血型不相合患者接受A型血浆未增加非致命并发症(HR 1.02;95%CI 0.80-1.30),无溶血性输血反应报告。作者认为A型应急释放血浆是需要大输血患者的可接受选择,尤其当AB型不易获得时。

要点

  • 在预测需大输血的创伤患者中,A型相比AB型应急释放血浆未增加血栓栓塞率(HR 0.52;95%CI 0.31-0.90)。
  • A型相比AB型应急释放血浆的死亡率(HR 1.15;95%CI 0.91-1.45)与非致命并发症(HR 1.24;95%CI 0.87-1.77)结果不确定。
  • 血型不相合患者(B型或AB型接受A型血浆)未增加非致命并发症(HR 1.02;95%CI 0.80-1.30),无溶血性输血反应报告。
  • 584例接受至少1 U应急释放血浆者中,462例(79.1%)接受AB型、122例(20.9%)接受A型。
  • 作者认为A型应急释放血浆是需要大输血患者的可接受选择,尤其当AB型不易获得时。

适用人群与场景

  • 预测需大输血的急性出血创伤患者,在血型鉴定完成前接受应急释放血浆。
  • 本分析纳入Pragmatic, Randomized, Optimal Platelet and Plasma Ratios试验中680例预测需大输血的患者,其中584例(85.9%)接受至少1 U应急释放血浆。

研究设计与关键结果

  • 研究类型:Pragmatic, Randomized, Optimal Platelet and Plasma Ratios试验的二次分析。
  • 样本量:680例预测需大输血患者,584例(85.9%)接受至少1 U应急释放血浆纳入分析;462例(79.1%)接受AB型、122例(20.9%)接受A型应急释放血浆。
  • 主要终点:以HR 1.35为非劣效界值,A型相比AB型应急释放血浆未增加血栓栓塞率(HR 0.52;95%CI 0.31-0.90)。
  • 死亡率:A型相比AB型应急释放血浆HR 1.15(95%CI 0.91-1.45),结果不确定。
  • 非致命并发症:A型相比AB型应急释放血浆HR 1.24(95%CI 0.87-1.77),结果不确定。
  • 亚组分析:血型不相合患者(B型或AB型接受A型应急释放血浆)非致命并发症HR 1.02(95%CI 0.80-1.30)。
  • 无溶血性输血反应报告。

证据类型、等级与局限

  • 证据类型:随机试验的二次分析。
  • 证据等级:治疗/管理 level IV;预后 level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为A型应急释放血浆是需要大输血患者的可接受选择,尤其当AB型应急释放血浆不易获得时。
  • 作者认为使用应急释放血浆在大输血患者中常见,有助于对失血患者实施快速平衡复苏。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Both groups A and AB plasma have been approved for emergency-release transfusion in acutely bleeding trauma patients before blood grouping being performed. The safety profile associated with this practice has not been well characterized, particularly in patients requiring massive transfusion.

METHODS: This secondary analysis of the Pragmatic, Randomized, Optimal Platelet and Plasma Ratios trial examined whether exposure to group A emergency-release plasma (ERP) was noninferior to group AB ERP. We also examined patients whose blood groups were compatible with group A ERP versus patients whose blood groups were incompatible with group A ERP. Outcomes included 30-day mortality and complication rates including systemic inflammatory response syndrome, infection, renal injury, pulmonary dysfunction, and thromboembolism.

RESULTS: Of the 680 patients predicted to receive a massive transfusion, 584 (85.9%) received at least 1 U of ERP. Of the 584 patients analyzed, 462 (79.1%) received group AB and 122 (20.9%) received group A ERP. Using a hazard ratio (HR) of 1.35 as the noninferiority margin, transfusion with group A versus group AB ERP was not associated with increased thromboembolic rates (HR, 0.52; 95% confidence interval [CI], 0.31-0.90). Mortality (HR, 1.15; 95% CI, 0.91-1.45) and nonfatal complication rates (HR, 1.24; 95% CI, 0.87-1.77) were inconclusive. In the subgroup analysis, transfusion with incompatible ERP (group B or AB patients receiving group A ERP) was not associated with increased nonfatal complications (HR, 1.02; 95% CI, 0.80-1.30). There were no reported hemolytic transfusion reactions.

CONCLUSION: The use of ERP is common in patients requiring massive transfusion and facilitates the rapid balanced resuscitation of patients who have sustained blood loss. Group A ERP is an acceptable option for patients requiring massive transfusion, especially if group AB ERP is not readily available.

LEVEL OF EVIDENCE: Therapeutic/Care Management, level IV; Prognostic, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. de Roulet A, Kerby JD, Weinberg JA, et al. Group A emergency-release plasma in trauma patients requiring massive transfusion. J Trauma Acute Care Surg. 2020. PMID: 32890339. doi:10.1097/TA.0000000000002903

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。